Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 63 posts
November 9, 2021 | Blogs
Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?
CBPartners' Digital Therapeutics and Health Technology Expertise Team investigates reimbursement for Opioid Use Disorder (OUD) DTx in the US.
November 2, 2021 | Blogs
Historically there has been limited competition for biologic drugs resulting in fewer choices and higher prices for patients. This analysis explores insulin products in the USA and EU to compare the approval pathways.
October 27, 2021 | Blogs
Despite surpassing the challenge of FDA approval, there are now a wide range of implications for health care access and coverage in the U.S for aducanumab, a treatment for Alzheimer's Disease.
October 19, 2021 | Blogs
Explore themes from biotech and investors in the cell and gene therapy space, as well as future-facing cell and gene therapy trends, new developments in the space, as well as what’s next.
October 6, 2021 | Blogs
Some cell and gene therapies without a curative promise have shown encouraging results for patients with chronic disorders, however manufacturers need to carefully design a value strategy for their non-curative assets to ensure maximum access and uptake in their target markets.